HEPCIDIN MIMETIC PEPTIDES AND USES THEREOF

• US 20150284429A1
• Filed: 04/07/2015
• Published: 10/08/2015
• Est. Priority Date: 04/07/2014
• Status: Active Grant

• Current Assignee: La Jolla Pharmaceutical Company (Innoviva, Inc.)
• Original Assignee: Merganser Biotech, Inc.
• Inventors: MERUTKA, GENE SCOTT
• Granted Patent: US 9,315,545 B2
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 7/06 Antianaemics
• CPC Class Codes: C07K 7/02 Linear peptides containing at least one abnormal peptide link
• CPC Class Codes: C07K 7/06 having 5 to 11 amino acids

Abstract

Compounds and methods are described herein that can be used to treat subjects for conditions related to hepcidin activity, such as but not limited diseases of iron metabolism, beta thalassemia, hemochromatosis, iron-loading anemias, alcoholic liver disease, or chronic hepatitis C.

Claims

1-67. -67. (canceled)

68. A compound, or pharmaceutically acceptable thereof, of formula

69. The compound, or pharmaceutically acceptable salt thereof, of claim 68, wherein R₁ is —

S—

CH₃.

70. The compound, or pharmaceutically acceptable salt thereof, of claim 68, wherein R₁ is H.

71. A pharmaceutical composition comprising a compound, or pharmaceutically acceptable thereof, of formula

72. The pharmaceutical composition of claim 71 further comprising a pharmaceutically acceptable excipient.

73. The pharmaceutical composition of claim 71, wherein R₁ is —

S—

CH₃.

74. The pharmaceutical composition of claim 71, wherein R₁ is H.

75. A method of reducing serum iron concentration in a subject comprising administering to the subject a pharmaceutical composition comprising a compound, or pharmaceutically acceptable thereof, of formula

76. The method of claim 75, wherein R₁ is —

S—

CH₃.

77. The method of claim 75, wherein R₁ is H.

78. The method of claim 75, wherein the subject is a subject in need thereof.

79. A method of treating a subject for beta thalassemia comprising administering to the subject a pharmaceutical composition comprising a compound, or pharmaceutically acceptable thereof, of formula

80. The method of claim 79, wherein R₁ is —

S—

CH₃.

81. The method of claim 79, wherein R₁ is H.

82. The method of claim 79, wherein the subject is a subject in need thereof.